All Updates

All Updates

icon
Filter
FDA approval
Orchard Therapeutics’ Lenmeldy receives FDA approval; becomes first-of-its kind treatment for children with genetic disorder
Cell & Gene Therapy
Mar 18, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Product updates
Partnerships
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Mar 18, 2024

Orchard Therapeutics’ Lenmeldy receives FDA approval; becomes first-of-its kind treatment for children with genetic disorder

FDA approval

  • UK-based Orchard Therapeutics has received FDA approval for gene therapy "Lenmeldy" to treat children suffering from metachromatic leukodystrophy (MLD), a rare genetic disease. The therapy's price has not been disclosed.

  • Lenmeldy is a one-time therapy for children experiencing certain stages of MLD and uses the patient's own hematopoietic stem cells. The FDA reported that Lenmeldy substantially reduced the risk of severe motor impairment or death compared to untreated children. In December 2020, the therapy was approved and marketed in the European Union under the brand name "Libmeldy."

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.